Avella has earned this distinction for the 11th straight year, putting it in the top .1 percent of companies ever ranked by Inc. Magazine nationwide
Rebecca Shanahan joins three decades of groundbreaking entrepreneurs in healthcare.
Denver, CO – EY just honored Rebecca Shanahan, CEO of Avella Specialty Pharmacy and National Association of Specialty Pharmacy (NASP) president, with the Entrepreneur Of The Year® 2017 Award in the Mountain Desert region’s healthcare category. The award was selected by an independent panel of judges, recognizing entrepreneurs who excel in areas like innovation, financial performance, and personal commitment to their businesses and communities. Avella provides powerful medications used to treat serious illnesses including Hepatitis C, HIV, cancer and other complex, often life-threatening conditions. What began as a single pharmacy in Scottsdale nearly two decades ago is now one of the fastest-growing companies in the nation. Today, Avella houses its own clean room facilities, a national distribution center and community-based pharmacies across multiple states.
June 22, 2017 - Houston, TX, Advanced Pharma, Inc. d/b/a Avella of Houston (“Advanced Pharma”) is conducting a limited, voluntary recall due to Hospira Inc.’s (“Hospira”) June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by Advanced Pharma were repackaged and/or compounded at its Houston, Texas facility using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall: https://www.fda.gov/Safety/Recalls/ucm563383.htm.
June 15, 2017 - Houston, TX, Advanced Pharma, Inc. d/b/a Avella of Houston (“Advanced Pharma”) is voluntarily recalling all unexpired lots of Nitroglycerin products that were produced at Advanced Pharma’s Houston location between March 3, 2017 and May 31, 2017 to the hospital/user level. The recall is being issued based on laboratory test results indicating a lower than expected potency on certain lots of compounded NitroGlycerin Injection which would lead to a lower dose being administered. While the lower than expected potency results affected only certain lots of Nitroglycerin, in an abundance of caution, Advanced Pharma is recalling all unexpired lots of NitroGlycerin. To date, Advanced Pharma has not received any reports of product complaints and/or adverse events related to the products.
Avella Specialty Pharmacy has issued its Outlook on Oncology report, a fact-based analysis that depicts the current state of the oncology industry and explores the trends, opportunities and new developments affecting cancer care delivery. The new white paper is available for download at avella.com/outlook-oncology
The data-rich report details how many of the changes taking place in the healthcare industry as a whole are specifically impacting the oncology space. One example cited is the real-time information exchange happening between healthcare stakeholders, which is enabling greater coordination of care for oncology patients. In a similar manner, new oncology-focused Accountable Care Organizations (ACOs) are fostering greater collaboration among payers, providers and pharmacies.
Calling on Centers for Medicare & Medicaid Services to Curb Below-Cost Reimbursement to Specialty Pharmacies by Pharmaceutical Benefit Managers, to Clarify Medicare Definitions, & Promote Accurate & Responsible Reimbursement
Direct & Indirect Remuneration (DIR) fees erode access to vital clinical services & breakthrough drugs for the most vulnerable Americans, increasing costs across the board & negatively impacting seniors & their caregivers, pharmacies, & taxpayers that fund Medicare
Last week, Frier Levitt, LLC; and the National Association of Specialty Pharmacy (NASP) published a white paper describing the advent and negative consequences of Direct and Indirect Remuneration (DIR) fees. America’s seniors need the Centers for Medicare and Medicaid Services (CMS) to take immediate action to stop Pharmaceutical Benefits Managers (PBMs) from levying inappropriate, unreasonable and unsustainable DIR fees on specialty pharmacies.
VIENNA, VA / PHOENIX, AZ, March 28, 2017 – Today, Allergy & Asthma Network and Avella Specialty Pharmacy released a new white paper to underscore the significant risks related to latex allergies and the use of latex in healthcare. Specifically, there is substantial confusion as to the meaning of “latex free” in healthcare. In fact, the FDA has urged manufacturers to drop the term “latex free” or a ”does not contain latex” claim from labels, because of the challenge to ensure a product is completely devoid of natural rubber latex proteins that cause allergic reactions. According to the FDA, these labeling techniques are not sufficiently specific, not necessarily scientifically accurate, and may be misunderstood and applied too widely.
HOUSTON, Feb. 23, 2017 - Advanced Pharma, Inc. d/b/a Avella of Houston is conducting a voluntary recall of all unexpired sterile injectable products labeled "latex free" that were produced at Advanced Pharma, Inc.'s Houston location between September 1, 2016 and February 16, 2017 to the user level (hospitals and institutions) because such products may contain synthetic latex and/or natural latex.
Avella and Advanced Pharma have been unable to confirm with clarity whether its "latex free" label statements are accurate in all cases and are therefore conducting this recall in an abundance of caution. The risk of potential adverse events related to a latex allergy, while rare, can range from local site reactions including swelling and inflammation to allergic reactions, which could be life-threatening to users who are sensitive to latex. These products were not distributed directly to patients or consumers, but rather to healthcare facilities (hospitals and institutions).
Avella has announced that it has been selected by Clovis Oncology to distribute RUBRACATM, an oral therapy for ovarian cancer. The drug was recently approved by the FDA for patients with advanced ovarian cancer who have previously received two types of chemotherapy agents.